Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study.
Preman KumarathuraiChristian AnholmOlav W NielsenOle P KristiansenJens MølvigSten MadsbadSteen B HaugaardAhmad SajadiehPublished in: Cardiovascular diabetology (2016)
In conclusion, liraglutide did not improve the systolic function of the left ventricle during DSE or the exercise capacity in patients with T2D and stable CAD. Clinical Trial Registration http://www.clinicaltrials.gov (unique identifier: NCT01595789).
Keyphrases
- double blind
- placebo controlled
- clinical trial
- type diabetes
- blood pressure
- phase ii
- left ventricular
- heart failure
- study protocol
- phase iii
- coronary artery disease
- open label
- mitral valve
- pulmonary hypertension
- cardiovascular disease
- pulmonary artery
- phase ii study
- insulin resistance
- atrial fibrillation
- weight loss
- pulmonary arterial hypertension